Mr Greg Shaw

Tel: 02034478454
Fax: 02034564901
Email: Gregory.Shaw@uclh.nhs.uk

Location:
University College Hospital at Westmoreland Street

Specialities:
Urological Cancers, Prostate Cancer

Professional background

  • Consultant Urological Surgeon at University College London Hospitals NHS Foundation Trust July 2015 - Present
  • Honorary Senior Lecturer, UCL
  • Specialist Robotic surgery and Uro-oncology practice. Honorary Consultant at Barts Health.
  • NIHR North Thames Clinical Research Network, Urology Lead. Jan '16 to present
  • Associate editor Uro-oncology- British Journal of Urology International Knowledge, July '15 to present
  • Royal College of Surgeons of England, Fellow in Robotic Urological Surgery at The Lister Hospital, August 2014 - July 2015
  • NIHR Clinical Lecturer in Urology at Cambridge University, June 2010 - August 2014
  • Specialist registrar at North London/East of England Deanery, September 2006 - June 2010
  • Clinical Research Fellow in Uro-Oncology- St Bartholomews Hospital, Oct ‘04 to Oct ‘06
  • Clinical Fellow in Urology, The Institute of Urology, Feb '03- Oct '04
  • Basic Surgical Trainee - Barts Health and the Royal London Hospital
  • MD - “An Investigation into the Prevention and Treatment of Androgen Independence in Adenocarcinoma of the Prostate”. 2007 University of London.
  • MBBS - Barts and the Royal London 1999
  • BSc - Experimental pathology- University of London 1998

Research interests

Current research:

  1. The use of frozen section analysis during radical prostatectomy to promote nerve sparing and improve quality of life.
  2. Ex-vivo prostate biopsy methodology to harvest fresh tissue for research.

Previously

  1. Chief Investigator on clinical study- “The use of neoadjuvant degarelix to study the early effects of castration on human prostate cancer”. (REC:11/H0311/2)
  2. Chief investigator on clinical study- “Understanding the biology of advanced prostate cancer by molecular biology study of tissue from metastases”. (REC:12/EE/0046)

Publications

Peer reviewed papers

  1. Shaw GL, Whitaker H, Corcoran M, Warren A, Neal DE, The rapid effects of castration on human prostate cancer. Eur Urol. 2015 Nov 10 PMID: 26572708
  2. Vasdev N,Agarwal S, Rai B, Soosainathan A, Shaw G, Chang S, Gowrie Mohan-S, Adshead J Intraoperative frozen section of the prostate to reduces the risk of positive margin whilst ensuring nerve sparing in patients with Intermediate and high-risk prostate cancer undergoing robotic radical prostatectomy – First Reported UK Series. Accepted, Current Urology 2015
  3. Asim M, Massie C, Orafidiya F, Shaw G and Neal DE. Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015 Dec 11;108(5). 2016 May. PMID:26657335
  4. Pertega-Gomes N, Vizcaino JR , Felisbino S, Warren AY, Shaw GL, Fryer L, Neal DE and Massie CE. MCT2 protein over-expression throughout prostate cancer progression impacts on oncogenic signaling and malignant phenotypes. In Press Oncotarget 2015 Jun 2. PMID:26035357
  5. Shaw GL, Thomas B, Dawson S, Srivastava G, Vowler S, Gnanapragasam V, Shah N, Warren A, Neal D. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer. 2014 May 13;110(10):2405-11. PMID: 24722183
  6. Sooriakumaran P, Srivastava A, Shariat SF, Shaw G, Roobol MJ, Tewari AK Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22,393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. 2013 Nov 24. PMID: 24290695.
  7. Lewis D, Boren J, Shaw GL, Bielik R, Ramos-Montoya A, Larkin T, Martins C, Neal DE, Soloviev D, Brindle K. Late imaging with [1-11C]acetate PET improves tumour contrast. J Nucl Med. 2014 Apr 28, PMID: 24777291.
  8. A.Ramos-Montoya, A Lamb, R. Russell, V. Theodorou, J. Boren, H.Bon, M.Vias, Shaw GL, N.L Sharma, H.E Scott, SL Vowler, T Carroll, CE Massie, WJ Howat, AY Warren, R. Wooster,I Mills, D.E. Neal. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. 2014 May 1;6(5):651-61. PMID: 24737870
  9. Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL, Performing cytoreductive nephrectomy following targeted Sunitinib therapy for metastatic renal cell carcinoma- a surgical perspective Urol Int. 2012;89(1):83-8.. PMID: 22614181.
  10. Gnanapragasam V, Shaw GL, Mason M, Neal D, Optimal therapy for high risk localised prostate cancer - should surgery be an option or a preferred primary treatment? BJU Int. 2011 Sep 27. doi: 10.1111/j.1464-410X.2011.10596.x. PMID: 21951841
  11. Boyd L, Xue L, Mao X, Li D, Beltran L, Shaw GL, Hines J, Chaplin T, Berney DM, Bryan D. Young BD, Lu YJ. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multi-focal prostate cancer. Genes Chromosomes Cancer. 2012 Jun;51(6):579-89. PMID: 22334418.
  12. Rouse P, Shaw GL, Ahmed H, Freeman A, Allen C, Emberton M. Multi-parametric Magnetic Resonance Imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53. PMID: 21701136
  13. Vasiljević N, Wu K, Brentnall A, Kim DC, Thorat MA., Kudahetti S, Mao X, Xue L, Yu Y, Shaw GL, Beltran L,. Lu YJ, Berney D, Cuzick J and Lorincz AT.Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer using Pyrosequencing. Dis Markers. 2011;30(4):151-61 2011. PMID: 21694441
  14. Shaw GL, Ioannou I, Gelister J, Briggs T. Management of Vesico Urethral Anastamosis Disruption after Radical Prostatectomy. Urol Int 84, No. 4, pp 436 - 439 , 2010, PMID: 20224267
  15. Nair R, Holdroyd D, Shaw GL, Gelister J. Reducing false passages: a novel technique for difficult urethral catheterization. Ann R Coll Surg Engl 2010; 92: 259, PMID: 20425888
  16. Tuffaha H, Shaw GL, Briggs T. Augmented bladder appearance under blue light, J Endourol. Journal of Endourology. June 2010, 24(6): 943-944. PMID: 20367243
  17. Dukic I, Shaw GL, Hussein M, Maraj B. A comparison of handwritten to computerised urological operative notes. Brit J. Med Surg Urol..(2010) 3,22-24
  18. Shaw GL and Bunce C. Flourescence Cystoscopy- How to do it. Photodiagnosis and Photodynamic Therapy. (2008) 5, 267—270 PMID:19356669
  19. Shaw GL., Emberton M.E, Morgan R, Berney D., Cuzick J, Oliver R.T.D. Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high grade prostate cancer. Brit J. Med Surg Urol. 2009 July 2 (4) 171-173.
  20. Shaw GL and Oliver RTD. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. J Surg Onc. Mar 2009 PMID:19269165
  21. Ahmed HU, Ishaq A, Zacharakis E, Shaw GL, Illing R, Allen C, Kirkham A,Emberton M. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2008 Nov 18. 321-3 PMID:19021611
  22. Shaw GL and Prowse DM. Inhibition of androgen independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signaling Cancer Cell Int. 2008 Mar 18;8:3. PMID:18348720
  23. Shaw GL, Ktori E, Price AM, Bisson I, Purkis P, McFaul S, Oliver RTD and Prowse DM. Hedgehog Signalling in Androgen Independent Prostate Cancer. European Urology 2008 Dec;54(6):1333-43. PMID:18262716
  24. Mao X, Shaw GL, James SY, Purkis P, Kudahett SK, Tsigan T, Kia1 S, B Young BD, Oliver RTD, Berney D, Prowse DM and Lu YJ. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian Journal of Andrology 2008 May;10(3):467-73. PMID:18385909
  25. Shaw GL and Patel HRH. Transdermal Oxybutynin: a review. Expert Opinion in Pharmacology 2007 Jun;3(3):435-9. PMID: 17539749
  26. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry N, Oliver RTD. International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1446 patients. BJUi 2007 May;99(5):1056-65. PMID: 17346277 Cited as a highlight of Urology. Framingham on Urology. Issue 2 2007
  27. Shaw GL, Purkiss T, Oliver RT, Prowse DM. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its Use as a Diagnostic Test in Prostate Cancer. Eur Urol 2006;50:153-4. PMID:17049717
  28. Shaw GL., Wah TM, Kellett M, Choong S.: Management of renal-vein perforation during a challenging percutaneous nephrolithotomy. J Endourol, 19: 722, 2005 PMID:16053363
  29. Symes A, Shaw GL, Corry, D, Choong S.: Pelvi-calyceal height, a predictor of success when treating lower pole stones with extracorporeal shockwave lithotripsy. Urol Res, 33: 297, 2005 PMID:15937708
  30. Shaw GL, Choong SK, and Fry C.: Encrustation of biomaterials in the urinary tract. Urol Res, 33: 17, 2005 PMID:15614579
  31. Khan MA, Shaw GL, and Paris AM.: Is microscopic haematuria a urological emergency? BJU Int, 90: 355, 2002 PMID 12175388

Book Chapters

  1. Shaw GL and Neal D, Chapter 73 The Prostate and Seminal Vesicles. Bailey and Love’s Short Practice of Surgery 27th Edition. Edward Arnold 2016
  2. Shaw GL. Neal DE. “Molecular Biology of Prostate cancer”, in Tewari A Prostate Cancer: A Comprehensive Perspective Elselvier 2011
  3. Shaw GL and Neal D, Chapter 73 The Prostate and Seminal Vesicles. Bailey and Love’s Short Practice of Surgery 26th Edition. Edward Arnold 2011

 

GMC/GDC number: 4626222